24 March 2022  
EMA/CHMP/172750/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Polivy 
polatuzumab vedotin 
On 24 March 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Polivy. The marketing authorisation holder for this medicinal product is Roche Registration GmbH. 
The CHMP adopted a new indication for the treatment of previously untreated diffuse large B-cell 
lymphoma. 
For information, the full indications for Polivy will be as follows:2 
Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone 
(R-CHP) is indicated for the treatment of adult patients with previously untreated 
diffuse large B-cell lymphoma (DLBCL). 
Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult 
patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates 
for haematopoietic stem cell transplant. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
